• レポートコード:QFJ1-6069 • 出版社/出版日:QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態:英文、PDF、118ページ • 納品方法:Eメール(納期:3日) • 産業分類:医薬品 |
Single User | ¥585,000 (USD3,900) | ▷ お問い合わせ |
Multi User | ¥877,500 (USD5,850) | ▷ お問い合わせ |
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
QYResearch社発行の本調査レポートでは、ウェット型黄斑変性症の世界市場(2016年~2027年)を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模(ルセンティス、アイレア、アバスチン、その他)、用途別市場規模(病院、診療所、研究機関、学術機関)、主要地域別市場規模(北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等)、企業情報などをまとめております。 ・市場概要 ・ウェット型黄斑変性症の市場動向 ・企業の競争状況、市場シェア ・ウェット型黄斑変性症の種類別市場規模と予測2016-2027(ルセンティス、アイレア、アバスチン、その他) ・ウェット型黄斑変性症の用途別市場規模と予測2016-2027(病院、診療所、研究機関、学術機関) ・ウェット型黄斑変性症の北米市場規模2016-2027(アメリカ、カナダ) ・ウェット型黄斑変性症の欧州市場規模2016-2027(ドイツ、フランス、イギリス等) ・ウェット型黄斑変性症のアジア市場規模2016-2027(日本、中国、韓国、インド、東南アジア等) ・ウェット型黄斑変性症の中南米市場規模2016-2027(メキシコ、ブラジル) ・ウェット型黄斑変性症の中東・アフリカ市場規模2016-2027(トルコ、サウジアラビア等) ・主要企業情報(Pfizer Inc.、F. Hoffmann-La Roche AG、Regeneron Pharmaceuticals, Inc.、Novartis AG、Bausch Health Companies Inc.、Apellis Pharmaceuticals Inc.、GlaxoSmithKline plc、Ophthotech Corporation、Gilead Sciences, Inc.、Alcon、Genzyme Corporation、Boehringer Ingelheim GmbH、EyeGate Pharmaceuticals, Inc.、EyeCyte, Inc.、PanOptica Inc) ・結論 |
Wet macular degeneration is a chronic eye disorder that induces vague vision or a blind spot in the patient’s visual field.
Market Analysis and Insights: Global Wet Macular Degeneration Market
The global Wet Macular Degeneration market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Wet Macular Degeneration market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Wet Macular Degeneration market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Wet Macular Degeneration market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Wet Macular Degeneration market.
Global Wet Macular Degeneration Scope and Market Size
Wet Macular Degeneration market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Wet Macular Degeneration market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
by Drug
Lucentis
Eylea
Avastin
Others
by Route of Administration
Intravitreal
Intravenous
Segment by Application
Hospitals
Clinics
Research Institutes
Academic Institutes
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Pfizer Inc.
F. Hoffmann-La Roche AG
Regeneron Pharmaceuticals, Inc.
Novartis AG
Bausch Health Companies Inc.
Apellis Pharmaceuticals Inc.
GlaxoSmithKline plc
Ophthotech Corporation
Gilead Sciences, Inc.
Alcon
Genzyme Corporation
Boehringer Ingelheim GmbH
EyeGate Pharmaceuticals, Inc.
EyeCyte, Inc.
PanOptica Inc
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Wet Macular Degeneration Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Lucentis
1.2.3 Eylea
1.2.4 Avastin
1.2.5 Others
1.3 Market by Application
1.3.1 Global Wet Macular Degeneration Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Research Institutes
1.3.5 Academic Institutes
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Wet Macular Degeneration Market Perspective (2016-2027)
2.2 Wet Macular Degeneration Growth Trends by Regions
2.2.1 Wet Macular Degeneration Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Wet Macular Degeneration Historic Market Share by Regions (2016-2021)
2.2.3 Wet Macular Degeneration Forecasted Market Size by Regions (2022-2027)
2.3 Wet Macular Degeneration Industry Dynamic
2.3.1 Wet Macular Degeneration Market Trends
2.3.2 Wet Macular Degeneration Market Drivers
2.3.3 Wet Macular Degeneration Market Challenges
2.3.4 Wet Macular Degeneration Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Wet Macular Degeneration Players by Revenue
3.1.1 Global Top Wet Macular Degeneration Players by Revenue (2016-2021)
3.1.2 Global Wet Macular Degeneration Revenue Market Share by Players (2016-2021)
3.2 Global Wet Macular Degeneration Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Wet Macular Degeneration Revenue
3.4 Global Wet Macular Degeneration Market Concentration Ratio
3.4.1 Global Wet Macular Degeneration Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Wet Macular Degeneration Revenue in 2020
3.5 Wet Macular Degeneration Key Players Head office and Area Served
3.6 Key Players Wet Macular Degeneration Product Solution and Service
3.7 Date of Enter into Wet Macular Degeneration Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Wet Macular Degeneration Breakdown Data by Type
4.1 Global Wet Macular Degeneration Historic Market Size by Type (2016-2021)
4.2 Global Wet Macular Degeneration Forecasted Market Size by Type (2022-2027)
5 Wet Macular Degeneration Breakdown Data by Application
5.1 Global Wet Macular Degeneration Historic Market Size by Application (2016-2021)
5.2 Global Wet Macular Degeneration Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Wet Macular Degeneration Market Size (2016-2027)
6.2 North America Wet Macular Degeneration Market Size by Type
6.2.1 North America Wet Macular Degeneration Market Size by Type (2016-2021)
6.2.2 North America Wet Macular Degeneration Market Size by Type (2022-2027)
6.2.3 North America Wet Macular Degeneration Market Size by Type (2016-2027)
6.3 North America Wet Macular Degeneration Market Size by Application
6.3.1 North America Wet Macular Degeneration Market Size by Application (2016-2021)
6.3.2 North America Wet Macular Degeneration Market Size by Application (2022-2027)
6.3.3 North America Wet Macular Degeneration Market Size by Application (2016-2027)
6.4 North America Wet Macular Degeneration Market Size by Country
6.4.1 North America Wet Macular Degeneration Market Size by Country (2016-2021)
6.4.2 North America Wet Macular Degeneration Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Wet Macular Degeneration Market Size (2016-2027)
7.2 Europe Wet Macular Degeneration Market Size by Type
7.2.1 Europe Wet Macular Degeneration Market Size by Type (2016-2021)
7.2.2 Europe Wet Macular Degeneration Market Size by Type (2022-2027)
7.2.3 Europe Wet Macular Degeneration Market Size by Type (2016-2027)
7.3 Europe Wet Macular Degeneration Market Size by Application
7.3.1 Europe Wet Macular Degeneration Market Size by Application (2016-2021)
7.3.2 Europe Wet Macular Degeneration Market Size by Application (2022-2027)
7.3.3 Europe Wet Macular Degeneration Market Size by Application (2016-2027)
7.4 Europe Wet Macular Degeneration Market Size by Country
7.4.1 Europe Wet Macular Degeneration Market Size by Country (2016-2021)
7.4.2 Europe Wet Macular Degeneration Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Wet Macular Degeneration Market Size (2016-2027)
8.2 Asia-Pacific Wet Macular Degeneration Market Size by Type
8.2.1 Asia-Pacific Wet Macular Degeneration Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Wet Macular Degeneration Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Wet Macular Degeneration Market Size by Type (2016-2027)
8.3 Asia-Pacific Wet Macular Degeneration Market Size by Application
8.3.1 Asia-Pacific Wet Macular Degeneration Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Wet Macular Degeneration Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Wet Macular Degeneration Market Size by Application (2016-2027)
8.4 Asia-Pacific Wet Macular Degeneration Market Size by Region
8.4.1 Asia-Pacific Wet Macular Degeneration Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Wet Macular Degeneration Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Wet Macular Degeneration Market Size (2016-2027)
9.2 Latin America Wet Macular Degeneration Market Size by Type
9.2.1 Latin America Wet Macular Degeneration Market Size by Type (2016-2021)
9.2.2 Latin America Wet Macular Degeneration Market Size by Type (2022-2027)
9.2.3 Latin America Wet Macular Degeneration Market Size by Type (2016-2027)
9.3 Latin America Wet Macular Degeneration Market Size by Application
9.3.1 Latin America Wet Macular Degeneration Market Size by Application (2016-2021)
9.3.2 Latin America Wet Macular Degeneration Market Size by Application (2022-2027)
9.3.3 Latin America Wet Macular Degeneration Market Size by Application (2016-2027)
9.4 Latin America Wet Macular Degeneration Market Size by Country
9.4.1 Latin America Wet Macular Degeneration Market Size by Country (2016-2021)
9.4.2 Latin America Wet Macular Degeneration Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Wet Macular Degeneration Market Size (2016-2027)
10.2 Middle East & Africa Wet Macular Degeneration Market Size by Type
10.2.1 Middle East & Africa Wet Macular Degeneration Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Wet Macular Degeneration Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Wet Macular Degeneration Market Size by Type (2016-2027)
10.3 Middle East & Africa Wet Macular Degeneration Market Size by Application
10.3.1 Middle East & Africa Wet Macular Degeneration Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Wet Macular Degeneration Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Wet Macular Degeneration Market Size by Application (2016-2027)
10.4 Middle East & Africa Wet Macular Degeneration Market Size by Country
10.4.1 Middle East & Africa Wet Macular Degeneration Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Wet Macular Degeneration Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Pfizer Inc.
11.1.1 Pfizer Inc. Company Details
11.1.2 Pfizer Inc. Business Overview
11.1.3 Pfizer Inc. Wet Macular Degeneration Introduction
11.1.4 Pfizer Inc. Revenue in Wet Macular Degeneration Business (2016-2021)
11.1.5 Pfizer Inc. Recent Development
11.2 F. Hoffmann-La Roche AG
11.2.1 F. Hoffmann-La Roche AG Company Details
11.2.2 F. Hoffmann-La Roche AG Business Overview
11.2.3 F. Hoffmann-La Roche AG Wet Macular Degeneration Introduction
11.2.4 F. Hoffmann-La Roche AG Revenue in Wet Macular Degeneration Business (2016-2021)
11.2.5 F. Hoffmann-La Roche AG Recent Development
11.3 Regeneron Pharmaceuticals, Inc.
11.3.1 Regeneron Pharmaceuticals, Inc. Company Details
11.3.2 Regeneron Pharmaceuticals, Inc. Business Overview
11.3.3 Regeneron Pharmaceuticals, Inc. Wet Macular Degeneration Introduction
11.3.4 Regeneron Pharmaceuticals, Inc. Revenue in Wet Macular Degeneration Business (2016-2021)
11.3.5 Regeneron Pharmaceuticals, Inc. Recent Development
11.4 Novartis AG
11.4.1 Novartis AG Company Details
11.4.2 Novartis AG Business Overview
11.4.3 Novartis AG Wet Macular Degeneration Introduction
11.4.4 Novartis AG Revenue in Wet Macular Degeneration Business (2016-2021)
11.4.5 Novartis AG Recent Development
11.5 Bausch Health Companies Inc.
11.5.1 Bausch Health Companies Inc. Company Details
11.5.2 Bausch Health Companies Inc. Business Overview
11.5.3 Bausch Health Companies Inc. Wet Macular Degeneration Introduction
11.5.4 Bausch Health Companies Inc. Revenue in Wet Macular Degeneration Business (2016-2021)
11.5.5 Bausch Health Companies Inc. Recent Development
11.6 Apellis Pharmaceuticals Inc.
11.6.1 Apellis Pharmaceuticals Inc. Company Details
11.6.2 Apellis Pharmaceuticals Inc. Business Overview
11.6.3 Apellis Pharmaceuticals Inc. Wet Macular Degeneration Introduction
11.6.4 Apellis Pharmaceuticals Inc. Revenue in Wet Macular Degeneration Business (2016-2021)
11.6.5 Apellis Pharmaceuticals Inc. Recent Development
11.7 GlaxoSmithKline plc
11.7.1 GlaxoSmithKline plc Company Details
11.7.2 GlaxoSmithKline plc Business Overview
11.7.3 GlaxoSmithKline plc Wet Macular Degeneration Introduction
11.7.4 GlaxoSmithKline plc Revenue in Wet Macular Degeneration Business (2016-2021)
11.7.5 GlaxoSmithKline plc Recent Development
11.8 Ophthotech Corporation
11.8.1 Ophthotech Corporation Company Details
11.8.2 Ophthotech Corporation Business Overview
11.8.3 Ophthotech Corporation Wet Macular Degeneration Introduction
11.8.4 Ophthotech Corporation Revenue in Wet Macular Degeneration Business (2016-2021)
11.8.5 Ophthotech Corporation Recent Development
11.9 Gilead Sciences, Inc.
11.9.1 Gilead Sciences, Inc. Company Details
11.9.2 Gilead Sciences, Inc. Business Overview
11.9.3 Gilead Sciences, Inc. Wet Macular Degeneration Introduction
11.9.4 Gilead Sciences, Inc. Revenue in Wet Macular Degeneration Business (2016-2021)
11.9.5 Gilead Sciences, Inc. Recent Development
11.10 Alcon
11.10.1 Alcon Company Details
11.10.2 Alcon Business Overview
11.10.3 Alcon Wet Macular Degeneration Introduction
11.10.4 Alcon Revenue in Wet Macular Degeneration Business (2016-2021)
11.10.5 Alcon Recent Development
11.11 Genzyme Corporation
11.11.1 Genzyme Corporation Company Details
11.11.2 Genzyme Corporation Business Overview
11.11.3 Genzyme Corporation Wet Macular Degeneration Introduction
11.11.4 Genzyme Corporation Revenue in Wet Macular Degeneration Business (2016-2021)
11.11.5 Genzyme Corporation Recent Development
11.12 Boehringer Ingelheim GmbH
11.12.1 Boehringer Ingelheim GmbH Company Details
11.12.2 Boehringer Ingelheim GmbH Business Overview
11.12.3 Boehringer Ingelheim GmbH Wet Macular Degeneration Introduction
11.12.4 Boehringer Ingelheim GmbH Revenue in Wet Macular Degeneration Business (2016-2021)
11.12.5 Boehringer Ingelheim GmbH Recent Development
11.13 EyeGate Pharmaceuticals, Inc.
11.13.1 EyeGate Pharmaceuticals, Inc. Company Details
11.13.2 EyeGate Pharmaceuticals, Inc. Business Overview
11.13.3 EyeGate Pharmaceuticals, Inc. Wet Macular Degeneration Introduction
11.13.4 EyeGate Pharmaceuticals, Inc. Revenue in Wet Macular Degeneration Business (2016-2021)
11.13.5 EyeGate Pharmaceuticals, Inc. Recent Development
11.14 EyeCyte, Inc.
11.14.1 EyeCyte, Inc. Company Details
11.14.2 EyeCyte, Inc. Business Overview
11.14.3 EyeCyte, Inc. Wet Macular Degeneration Introduction
11.14.4 EyeCyte, Inc. Revenue in Wet Macular Degeneration Business (2016-2021)
11.14.5 EyeCyte, Inc. Recent Development
11.15 PanOptica Inc
11.15.1 PanOptica Inc Company Details
11.15.2 PanOptica Inc Business Overview
11.15.3 PanOptica Inc Wet Macular Degeneration Introduction
11.15.4 PanOptica Inc Revenue in Wet Macular Degeneration Business (2016-2021)
11.15.5 PanOptica Inc Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Wet Macular Degeneration Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Lucentis
Table 3. Key Players of Eylea
Table 4. Key Players of Avastin
Table 5. Key Players of Others
Table 6. Global Wet Macular Degeneration Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Wet Macular Degeneration Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Wet Macular Degeneration Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Wet Macular Degeneration Market Share by Regions (2016-2021)
Table 10. Global Wet Macular Degeneration Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Wet Macular Degeneration Market Share by Regions (2022-2027)
Table 12. Wet Macular Degeneration Market Trends
Table 13. Wet Macular Degeneration Market Drivers
Table 14. Wet Macular Degeneration Market Challenges
Table 15. Wet Macular Degeneration Market Restraints
Table 16. Global Wet Macular Degeneration Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Wet Macular Degeneration Market Share by Players (2016-2021)
Table 18. Global Top Wet Macular Degeneration Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Wet Macular Degeneration as of 2020)
Table 19. Ranking of Global Top Wet Macular Degeneration Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Wet Macular Degeneration Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Wet Macular Degeneration Product Solution and Service
Table 23. Date of Enter into Wet Macular Degeneration Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Wet Macular Degeneration Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Wet Macular Degeneration Revenue Market Share by Type (2016-2021)
Table 27. Global Wet Macular Degeneration Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Wet Macular Degeneration Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Wet Macular Degeneration Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Wet Macular Degeneration Revenue Market Share by Application (2016-2021)
Table 31. Global Wet Macular Degeneration Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Wet Macular Degeneration Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Wet Macular Degeneration Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Wet Macular Degeneration Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Wet Macular Degeneration Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Wet Macular Degeneration Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Wet Macular Degeneration Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Wet Macular Degeneration Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Wet Macular Degeneration Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Wet Macular Degeneration Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Wet Macular Degeneration Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Wet Macular Degeneration Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Wet Macular Degeneration Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Wet Macular Degeneration Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Wet Macular Degeneration Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Wet Macular Degeneration Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Wet Macular Degeneration Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Wet Macular Degeneration Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Wet Macular Degeneration Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Wet Macular Degeneration Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Wet Macular Degeneration Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Wet Macular Degeneration Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Wet Macular Degeneration Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Wet Macular Degeneration Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Wet Macular Degeneration Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Wet Macular Degeneration Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Wet Macular Degeneration Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Wet Macular Degeneration Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Wet Macular Degeneration Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Wet Macular Degeneration Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Wet Macular Degeneration Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Wet Macular Degeneration Market Size by Country (2022-2027) & (US$ Million)
Table 63. Pfizer Inc. Company Details
Table 64. Pfizer Inc. Business Overview
Table 65. Pfizer Inc. Wet Macular Degeneration Product
Table 66. Pfizer Inc. Revenue in Wet Macular Degeneration Business (2016-2021) & (US$ Million)
Table 67. Pfizer Inc. Recent Development
Table 68. F. Hoffmann-La Roche AG Company Details
Table 69. F. Hoffmann-La Roche AG Business Overview
Table 70. F. Hoffmann-La Roche AG Wet Macular Degeneration Product
Table 71. F. Hoffmann-La Roche AG Revenue in Wet Macular Degeneration Business (2016-2021) & (US$ Million)
Table 72. F. Hoffmann-La Roche AG Recent Development
Table 73. Regeneron Pharmaceuticals, Inc. Company Details
Table 74. Regeneron Pharmaceuticals, Inc. Business Overview
Table 75. Regeneron Pharmaceuticals, Inc. Wet Macular Degeneration Product
Table 76. Regeneron Pharmaceuticals, Inc. Revenue in Wet Macular Degeneration Business (2016-2021) & (US$ Million)
Table 77. Regeneron Pharmaceuticals, Inc. Recent Development
Table 78. Novartis AG Company Details
Table 79. Novartis AG Business Overview
Table 80. Novartis AG Wet Macular Degeneration Product
Table 81. Novartis AG Revenue in Wet Macular Degeneration Business (2016-2021) & (US$ Million)
Table 82. Novartis AG Recent Development
Table 83. Bausch Health Companies Inc. Company Details
Table 84. Bausch Health Companies Inc. Business Overview
Table 85. Bausch Health Companies Inc. Wet Macular Degeneration Product
Table 86. Bausch Health Companies Inc. Revenue in Wet Macular Degeneration Business (2016-2021) & (US$ Million)
Table 87. Bausch Health Companies Inc. Recent Development
Table 88. Apellis Pharmaceuticals Inc. Company Details
Table 89. Apellis Pharmaceuticals Inc. Business Overview
Table 90. Apellis Pharmaceuticals Inc. Wet Macular Degeneration Product
Table 91. Apellis Pharmaceuticals Inc. Revenue in Wet Macular Degeneration Business (2016-2021) & (US$ Million)
Table 92. Apellis Pharmaceuticals Inc. Recent Development
Table 93. GlaxoSmithKline plc Company Details
Table 94. GlaxoSmithKline plc Business Overview
Table 95. GlaxoSmithKline plc Wet Macular Degeneration Product
Table 96. GlaxoSmithKline plc Revenue in Wet Macular Degeneration Business (2016-2021) & (US$ Million)
Table 97. GlaxoSmithKline plc Recent Development
Table 98. Ophthotech Corporation Company Details
Table 99. Ophthotech Corporation Business Overview
Table 100. Ophthotech Corporation Revenue in Wet Macular Degeneration Business (2016-2021) & (US$ Million)
Table 101. Ophthotech Corporation Recent Development
Table 102. Gilead Sciences, Inc. Company Details
Table 103. Gilead Sciences, Inc. Business Overview
Table 104. Gilead Sciences, Inc. Wet Macular Degeneration Product
Table 105. Gilead Sciences, Inc. Revenue in Wet Macular Degeneration Business (2016-2021) & (US$ Million)
Table 106. Gilead Sciences, Inc. Recent Development
Table 107. Alcon Company Details
Table 108. Alcon Business Overview
Table 109. Alcon Wet Macular Degeneration Product
Table 110. Alcon Revenue in Wet Macular Degeneration Business (2016-2021) & (US$ Million)
Table 111. Alcon Recent Development
Table 112. Genzyme Corporation Company Details
Table 113. Genzyme Corporation Business Overview
Table 114. Genzyme Corporation Wet Macular Degeneration Product
Table 115. Genzyme Corporation Revenue in Wet Macular Degeneration Business (2016-2021) & (US$ Million)
Table 116. Genzyme Corporation Recent Development
Table 117. Boehringer Ingelheim GmbH Company Details
Table 118. Boehringer Ingelheim GmbH Business Overview
Table 119. Boehringer Ingelheim GmbH Wet Macular Degeneration Product
Table 120. Boehringer Ingelheim GmbH Revenue in Wet Macular Degeneration Business (2016-2021) & (US$ Million)
Table 121. Boehringer Ingelheim GmbH Recent Development
Table 122. EyeGate Pharmaceuticals, Inc. Company Details
Table 123. EyeGate Pharmaceuticals, Inc. Business Overview
Table 124. EyeGate Pharmaceuticals, Inc. Wet Macular Degeneration Product
Table 125. EyeGate Pharmaceuticals, Inc. Revenue in Wet Macular Degeneration Business (2016-2021) & (US$ Million)
Table 126. EyeGate Pharmaceuticals, Inc. Recent Development
Table 127. EyeCyte, Inc. Company Details
Table 128. EyeCyte, Inc. Business Overview
Table 129. EyeCyte, Inc. Wet Macular Degeneration Product
Table 130. EyeCyte, Inc. Revenue in Wet Macular Degeneration Business (2016-2021) & (US$ Million)
Table 131. EyeCyte, Inc. Recent Development
Table 132. PanOptica Inc Company Details
Table 133. PanOptica Inc Business Overview
Table 134. PanOptica Inc Wet Macular Degeneration Product
Table 135. PanOptica Inc Revenue in Wet Macular Degeneration Business (2016-2021) & (US$ Million)
Table 136. PanOptica Inc Recent Development
Table 137. Research Programs/Design for This Report
Table 138. Key Data Information from Secondary Sources
Table 139. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Wet Macular Degeneration Market Share by Type: 2020 VS 2027
Figure 2. Lucentis Features
Figure 3. Eylea Features
Figure 4. Avastin Features
Figure 5. Others Features
Figure 6. Global Wet Macular Degeneration Market Share by Application: 2020 VS 2027
Figure 7. Hospitals Case Studies
Figure 8. Clinics Case Studies
Figure 9. Research Institutes Case Studies
Figure 10. Academic Institutes Case Studies
Figure 11. Wet Macular Degeneration Report Years Considered
Figure 12. Global Wet Macular Degeneration Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Wet Macular Degeneration Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Wet Macular Degeneration Market Share by Regions: 2020 VS 2027
Figure 15. Global Wet Macular Degeneration Market Share by Regions (2022-2027)
Figure 16. Global Wet Macular Degeneration Market Share by Players in 2020
Figure 17. Global Top Wet Macular Degeneration Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Wet Macular Degeneration as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Wet Macular Degeneration Revenue in 2020
Figure 19. Global Wet Macular Degeneration Revenue Market Share by Type (2016-2021)
Figure 20. Global Wet Macular Degeneration Revenue Market Share by Type (2022-2027)
Figure 21. North America Wet Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Wet Macular Degeneration Market Share by Type (2016-2027)
Figure 23. North America Wet Macular Degeneration Market Share by Application (2016-2027)
Figure 24. North America Wet Macular Degeneration Market Share by Country (2016-2027)
Figure 25. United States Wet Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Wet Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Wet Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Wet Macular Degeneration Market Share by Type (2016-2027)
Figure 29. Europe Wet Macular Degeneration Market Share by Application (2016-2027)
Figure 30. Europe Wet Macular Degeneration Market Share by Country (2016-2027)
Figure 31. Germany Wet Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Wet Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Wet Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Wet Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Wet Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Wet Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Wet Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Wet Macular Degeneration Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Wet Macular Degeneration Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Wet Macular Degeneration Market Share by Region (2016-2027)
Figure 41. China Wet Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Wet Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Wet Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Wet Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Wet Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Wet Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Wet Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Wet Macular Degeneration Market Share by Type (2016-2027)
Figure 49. Latin America Wet Macular Degeneration Market Share by Application (2016-2027)
Figure 50. Latin America Wet Macular Degeneration Market Share by Country (2016-2027)
Figure 51. Mexico Wet Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Wet Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Wet Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Wet Macular Degeneration Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Wet Macular Degeneration Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Wet Macular Degeneration Market Share by Country (2016-2027)
Figure 57. Turkey Wet Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Wet Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Wet Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Pfizer Inc. Revenue Growth Rate in Wet Macular Degeneration Business (2016-2021)
Figure 61. F. Hoffmann-La Roche AG Revenue Growth Rate in Wet Macular Degeneration Business (2016-2021)
Figure 62. Regeneron Pharmaceuticals, Inc. Revenue Growth Rate in Wet Macular Degeneration Business (2016-2021)
Figure 63. Novartis AG Revenue Growth Rate in Wet Macular Degeneration Business (2016-2021)
Figure 64. Bausch Health Companies Inc. Revenue Growth Rate in Wet Macular Degeneration Business (2016-2021)
Figure 65. Apellis Pharmaceuticals Inc. Revenue Growth Rate in Wet Macular Degeneration Business (2016-2021)
Figure 66. GlaxoSmithKline plc Revenue Growth Rate in Wet Macular Degeneration Business (2016-2021)
Figure 67. Ophthotech Corporation Revenue Growth Rate in Wet Macular Degeneration Business (2016-2021)
Figure 68. Gilead Sciences, Inc. Revenue Growth Rate in Wet Macular Degeneration Business (2016-2021)
Figure 69. Alcon Revenue Growth Rate in Wet Macular Degeneration Business (2016-2021)
Figure 70. Genzyme Corporation Revenue Growth Rate in Wet Macular Degeneration Business (2016-2021)
Figure 71. Boehringer Ingelheim GmbH Revenue Growth Rate in Wet Macular Degeneration Business (2016-2021)
Figure 72. EyeGate Pharmaceuticals, Inc. Revenue Growth Rate in Wet Macular Degeneration Business (2016-2021)
Figure 73. EyeCyte, Inc. Revenue Growth Rate in Wet Macular Degeneration Business (2016-2021)
Figure 74. PanOptica Inc Revenue Growth Rate in Wet Macular Degeneration Business (2016-2021)
Figure 75. Bottom-up and Top-down Approaches for This Report
Figure 76. Data Triangulation
Figure 77. Key Executives Interviewed